NVCR - NovoCure Limited
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
As of May 15, 2026: spot at $17.55, ATM IV 62.0%, max pain $18.00, net GEX $343.7K.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Market Cap
- $2.10B
- Beta
- 0.90
- 52-Week Range
- 9.82-20.06
- CEO
- Frank Leonard
- Employees
- 1,488
- IPO Date
- Oct 1, 2015
- Exchange
- NASDAQ
What NVCR Looks Like to Options Traders Today
IV rank of 13.9% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); positive net gamma exposure ($343.7K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (0.042) prices calls richer than puts, often reflecting upside speculation or squeeze risk.
What This Page Covers
The NVCR overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked NVCR overview questions
- What is NVCR?
- NVCR is the ticker symbol for NovoCure Limited, a listed security. NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. Listed on NASDAQ. NVCR is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the NVCR options snapshot look like today?
- As of May 15, 2026, the NVCR options snapshot shows spot at $17.55, ATM IV 62.0%, IV rank 13.9%, max pain $18.00, net GEX $343.7K, expected move 17.77%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are NVCR's key statistics?
- NovoCure Limited (NVCR) carries a market capitalization of $2.10B, beta of 0.90 relative to the broader market, 52-week range of 9.82-20.06. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does NVCR belong to?
- NovoCure Limited operates in the Healthcare sector, in the Medical - Instruments & Supplies industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare NVCR's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the NVCR data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).